Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 3 1Phase 1/2 1

Status

Terminated 2Completed 1Active not recruiting 1

Sponsor Class

OTHER 2NIH 2

Study Type

Interventional 4

Sponsor

Cancer Type

Gastrointestinal 4

Conditions

Breast Neoplasms 51Fallopian Tube Neoplasms 28Ovarian Neoplasms 23Carcinoma, Non-Small-Cell Lung 22Triple Negative Breast Neoplasms 15Pancreatic Neoplasms 13Breast Neoplasms, Male 11Lung Neoplasms 10Brenner Tumor 10Inflammatory Breast Neoplasms 7Uterine Cervical Neoplasms 5Endometrial Adenocarcinoma 5Adenocarcinoma of Lung 5Urinary Bladder Neoplasms 4Squamous Cell Carcinoma of Head and Neck 4Melanoma 4Cholangiocarcinoma 4Carcinoma, Ovarian Epithelial 4Adenocarcinoma, Bronchiolo-Alveolar 4Adenocarcinoma Of Esophagus 4Pleural Effusion, Malignant 3Pancreatic Adenocarcinoma 3Neoplasms 3Thymoma 2Neurotoxicity Syndromes 2Gallbladder Neoplasms 2Esophageal Neoplasms 2Endometrial Neoplasms 2Carcinosarcoma 2Breast Carcinoma In Situ 2

Interventions

Radiotherapy 22Fluorouracil 20Oxaliplatin 19Leucovorin 14Cisplatin 14Paclitaxel 10Radiation 8Irinotecan 8Docetaxel 7Capecitabine 7Cetuximab 6Carboplatin 6pembrolizumab 5Neoadjuvant Therapy 5Trastuzumab 4Taxes 4Chemotherapy, Adjuvant 4Panitumumab 3Microarray Analysis 3Immunohistochemistry 3Folfox protocol 3Epirubicin 3Biopsy 3tucatinib 2Surgical Procedures, Operative 2Reverse Transcriptase Polymerase Chain Reaction 2Magnetic Resonance Spectroscopy 2Gene Expression Profiling 2Gefitinib 2Everolimus 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Has results × Adenocarcinoma Of Esophagus × Taxes × Clear all
NCT01196390 2026-06-02

Radiation Therapy, Paclitaxel, and Carboplatin With or Without Trastuzumab in Treating Patients With Esophageal Cancer

National Cancer Institute (NCI)

Phase 3 Completed
203 enrolled 22 charts
Gastrointestinal

Adenocarcinoma Of Esophagus, Esophageal Neoplasms

NCT01142388 2026-05-29

Paclitaxel With or Without Cixutumumab as Second-Line Therapy in Treating Patients With Metastatic Esophageal Cancer or Gastroesophageal Junction Cancer

National Cancer Institute (NCI)

Phase 2 Active not recruiting
94 enrolled 8 charts
Gastrointestinal

Adenocarcinoma Of Esophagus, Esophageal Squamous Cell Carcinoma, Esophageal Neoplasms

NCT02530437 2023-07-10

Taladegib, Paclitaxel, Carboplatin, and Radiation Therapy in Treating Patients With Localized Esophageal or Gastroesophageal Junction Cancer

M.D. Anderson Cancer Center

Phase 1/2 Terminated
7 enrolled 11 charts
Gastrointestinal

Adenocarcinoma Of Esophagus

NCT02392377 2018-02-13

Molecular Phenotyping in Predicting Response in Patients With Stage IB-III Esophageal Cancer Receiving Combination Chemotherapy

Case Comprehensive Cancer Center

Phase 2 Terminated
1 enrolled 5 charts
Gastrointestinal

Adenocarcinoma Of Esophagus

Data powered by HemOnc (CC BY 4.0) Colophon âš¡